Arix Bioscience plc

Plus: Sirnaomics promotes Lebel to CMO and updates from Enavate Sciences, Avoro Ventures, Eagle, Calliditas, 20Med 

Plus: RTW acquiring Arix Bioscience, and updates from Aldeyra, AbbVie, Silence, Lilly, Sitryx and more

Plus: Hennemand joins Covant as CEO and updates from Invitae, Immunome, Antiva, Omeros, Actimed and RegCell 

Plus: PureTech hires Arix CEO Lyne and updates from InterVenn, Veracyte, Arcutis, Strata, Sanotize, Caribou, Mati

Plus: New funds for BGV, Modi; Arix reviewing alternatives; and updates from Bicycle, Roche, Causaly, Neuren-Acadia  

Plus: Prevail, Scribe in gene editing deal and updates from Ensoma, NewLimit and Drug Farm

Backed with $145M since 2020, the biotech has a Phase IIa molecule for atopic dermatitis, plus at least two preclinical programs

Ensoma raises $85M in series B led by Arix, 5AM and acquires gene editing company Twelve Bio

Investor confidence had run high in Imara, but twin failures dash hopes for lead asset

Plus: LianBio’s infigratinib approved for pilot, Takeda, Arcutis, Sorriso and more